Abstract
Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Current Drug Delivery
Title: Particulate and Vesicular Drug Carriers in the Management of Tuberculosis
Volume: 3 Issue: 1
Author(s): Rachna Rastogi, Yasmin Sultana, Asgar Ali and Mohammed Aqil
Affiliation:
Keywords: antitubercular drugs, pulmonary tuberculosis, liposomes, niosomes, microspheres, nanoparticles, parenteral, inhalational and oral therapy, patient compliance
Abstract: Although oral drug therapy for tuberculosis exists and is widely followed, its major drawbacks are lack of patient compliance and development of adverse effects like hepatotoxicity on long term use. Absence of new therapeutic agents and the above mentioned demerits have led to search for alternative methods for delivery of antitubercular agents. Colloidal drug carriers, a popularly utilized delivery system has been deeply explored for the cause. The article discusses the advances in the management of tuberculosis by the use of particulate and vesicular drug carriers by parenteral, inhalational and oral routes. Use of this delivery strategy has led to massive reduction in the dosage resulting in toxicity alleviation. As a number of studies have already been undertaken in experimental models, it will be a promising tool in the prevention of relapse and successful treatment of tuberculosis in patients.
Export Options
About this article
Cite this article as:
Rastogi Rachna, Sultana Yasmin, Ali Asgar and Aqil Mohammed, Particulate and Vesicular Drug Carriers in the Management of Tuberculosis, Current Drug Delivery 2006; 3 (1) . https://dx.doi.org/10.2174/156720106775197448
DOI https://dx.doi.org/10.2174/156720106775197448 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Streptococcal Collagen-like Protein 1 Binds Wound Fibronectin: Implications in Pathogen Targeting
Current Medicinal Chemistry Edible Transgenic Plant Vaccines for Different Diseases
Current Pharmaceutical Biotechnology Graphical Abstracts
Letters in Drug Design & Discovery Isoniazid: an Update on the Multiple Mechanisms for a Singular Action
Current Medicinal Chemistry Rapid and Convenient CuCl2 Catalysed Microwave-Assisted Synthesis of Novel Spiro [indoline-3,4'-quinoline] Derivatives
Current Microwave Chemistry The Effects of Melatonin on the Oxidative Stress and Duration of Atrial Fibrillation after Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanocarriers as Prospective Approach in Effective Management of Acne Vulgaris
Micro and Nanosystems A Brief Review of the Computational Identification of Antifreeze Protein
Current Organic Chemistry Tuberculous Pericarditis
Current Cardiology Reviews 2', 4'-dihydroxy-3, 4-methylenedioxychalcone Activate Mitochondrial Apoptosis of Ehrlich Ascites Carcinoma Cells
Current Drug Therapy Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods
Current Drug Targets Antibacterial Activities of Flavonoids: Structure-Activity Relationship and Mechanism
Current Medicinal Chemistry Pyrazole and imidazo[1,2-b]pyrazole Derivatives as New Potential Antituberculosis Agents
Medicinal Chemistry Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Current Drug Safety Safety Issues of Vitamin D Supplementation
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine: Potential Devices for Diagnostics
Recent Patents on Nanomedicine Small Molecules for the Activation of Human γ δ T Cell Responses Against Infection
Recent Patents on Anti-Infective Drug Discovery Liposomes as Nanovaccine Delivery Systems
Current Topics in Medicinal Chemistry Genetic Mapping of Pharmacogenetic Regulatory Variation
Current Pharmaceutical Design Cytotoxic and Apoptotic Effect of <i>Iris taochia</i> Plant Extracts on Human Breast Cancer (MCF-7) Cells
Current Proteomics